ArticleBMC microbiology2014
Development of cross-resistance by Aspergillus fumigatus to clinical azoles following exposure to prochloraz, an agricultural azole.
Article in BMC microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 66 citations in OpenAlex.
- Antifungal Activity of a Postbiotic Cell-free Supernatant of Lactiplantibacillus plantarum from Pulicaria jaubertii against Aspergillus fumigatus and Candida albicans.BMC complementary medicine and therapies · 2026Article
- Addressing Critical Fungal Pathogens Under a One Health Perspective: Key Insights from the Portuguese Association of Medical Mycology.Mycopathologia · 2025Review
- Activity of Azole and Non-Azole Substances AgainstInternational journal of molecular sciences · 2025Article
- The mitochondrial protein Bcs1A regulates antifungal drug tolerance by affecting efflux pump expression in the filamentous pathogenic fungusMicrobiology spectrum · 2024Article
- Azole resistance mechanisms and population structure of the human pathogenApplied and environmental microbiology · 2024Article
- Fungal Colonization of the Airways of Patients with Cystic Fibrosis: the Role of the Environmental Reservoirs.Mycopathologia · 2024Review
- Multicentric Study on the Clinical Mycology Capacity and Access to Antifungal Treatment in Portugal.Mycopathologia · 2024Article
- Antifungal resistance: why are we losing this battle?Future microbiology · 2024Review
- Novel Clinical and Laboratorial Challenges in Aspergillosis.Microorganisms · 2022Article
- Fungicide effects on human fungal pathogens: Cross-resistance to medical drugs and beyond.PLoS pathogens · 2021Review
- Selection and Amplification of Fungicide Resistance inMicroorganisms · 2021Review
- Fungal Genomics in Respiratory Medicine: What, How and When?Mycopathologia · 2021Review
- Preliminary Characterization of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity.Antimicrobial agents and chemotherapy · 2021Article
- Discovery of fungal surface NADases predominantly present in pathogenic species.Nature communications · 2021Article
- Genetic and Phenotypic Characterization of in-Host Developed Azole-ResistantJournal of fungi (Basel, Switzerland) · 2021Article
- Mechanisms of triazole resistance in Aspergillus fumigatus.Environmental microbiology · 2020Review
- Hazard of agricultural triazole fungicide: Does cyproconazole induce voriconazole resistance in Aspergillus fumigatus isolates?Current medical mycology · 2020Article
- FKS1 mutation associated with decreased echinocandin susceptibility of Aspergillus fumigatus following anidulafungin exposure.Scientific reports · 2020Article
- Three-Locus Sequence Identification and Differential Tebuconazole Sensitivity Suggest NovelPathogens (Basel, Switzerland) · 2020Article
- A 23 bpFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to unveil whether azole antifungals used in agriculture, similar to the clinical azoles used in humans, can evoke resistance among relevant human pathogens like Aspergillus fumigatus, an ubiquitous agent in nature. Additionally, cross-resistance with clinical azoles was investigated. Antifungal susceptibility testing of environmental and clinical isolates of A. fumigatus was performed according to the CLSI M38-A2 protocol. In vitro induction assays were conducted involving daily incubation of susceptible A. fumigatus isolates, at 35°C and 180 rpm, in fresh GYEP broth medium supplemented with Prochloraz (PCZ), a potent agricultural antifungal, for a period of 30 days. Minimal inhibitory concentrations (MIC) of PCZ and clinical azoles were monitored every ten days. In order to assess the stability of the developed MIC, the strains were afterwards sub-cultured for an additional 30 days in the absence of antifungal. Along the in vitro induction process, microscopic and macroscopic cultural observations were registered.
resultsMIC of PCZ increased 256 times after the initial exposure; cross-resistance to all tested clinical azoles was observed. The new MIC value of agricultural and of clinical azoles maintained stable in the absence of the selective PCZ pressure. PCZ exposure was also associated to morphological colony changes: macroscopically the colonies became mostly white, losing the typical pigmentation; microscopic examination revealed the absence of conidiation.
conclusionsPCZ exposure induced Aspergillus fumigatus morphological changes and an evident increase of MIC value to PCZ as well as the development of cross-resistance with posaconazole, itraconazole and voriconazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.